<DOC>
	<DOCNO>NCT00558428</DOCNO>
	<brief_summary>The primary objective trial ( ) demonstrate fixed-dose combination T40/A5 fixed-dose combination T80/A5 superior reduce blood pressure eight week compare A5 ( b ) demonstrate fixed-dose combination T40/A5 fixed-dose combination T80/A5 inferior reduce blood pressure eight week compare A10 ( c ) demonstrate incidence oedema fixed-dose combination T40/A5 pool fixed-dose combination T80/A5 superior ( less oedema ) A10 patient fail respond adequately six week treatment A5 .</brief_summary>
	<brief_title>Telmisartan/Amlodipine ( 80/5 ) vs. Telmisartan/Amlodipine ( 40/5 ) vs. Amlodipine 10 5 Resistant Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>1. patient age least 18 year date signing consent form 2. diagnosis essential hypertension blood pressure adequately control enrolment study 3. failure respond adequately six week treatment amlodipine 5 mg monotherapy 4. able stop current antihypertensive therapy without unacceptable risk patient ( Investigator 's decision ) 5. willing able provide write informed consent ( accordance Good Clinical Practice local legislation ) . 1. practise acceptable mean birth control plan continue use acceptable mean birth control throughout study agree submit pregnancy test participation trial . Acceptable method birth control include transdermal patch , oral , implantable injectable contraceptive , sexual abstinence vasectomise partner . 2. know suspected secondary hypertension 3. mean seat systolic blood pressure ( SBP ) 200 mmHg and/or mean seat diastolic blood pressure ( DBP ) 120 mmHg Visit 1 2 mean seat SBP 180 mmHg and/or mean seat DBP 120 mmHg end runin period ( Visit 3 ) 4. clinically significant hepatic impairment ( e.g . clinically significant cholestasis , biliary obstructive disorder hepatic insufficiency ) 5. severe renal impairment ( e.g . serum creatinine &gt; 3.0 mg/dL &gt; 265 mcmol/L , know creatinine clearance &lt; 30mL/min clinical marker severe renal impairment ) 6. bilateral renal artery stenosis renal artery stenosis solitary kidney postrenal transplant 7. clinically relevant hyperkalaemia 8. uncorrected volume sodium depletion . 9. primary aldosteronism . 10. hereditary fructose lactose intolerance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>